

CONFIDENTIAL



NIAGARA HEALTH SYSTEM
SYSTÈME DE SANTÉ DE NIAGARA
TOGETHER IN EXCELLENCE - LEADERS IN HEALTHCARE

Report on Regional Laboratory Services

March, 2005



TABLE OF CONTENTS

I. INTRODUCTION AND BACKGROUND..... 3

PROJECT PURPOSE AND OBJECTIVES 3

APPROACH AND METHODOLOGY 3

DATA COLLECTION ACTIVITIES 4

Interview Program..... 4

Site Visits..... 5

FINANCIAL AND VOLUME ANALYSIS 5

II. KEY FINDINGS OF THE OPERATIONAL REVIEW OF LABORATORY SERVICES 8

NIAGARA HEALTH SYSTEM LABORATORY OVERVIEW 8

Quality Assurance..... 10

Transportation Networks 10

Laboratory Information System (LIS)..... 10

COMPARISONS..... 11

Graphs 11

Graphs 12

 Cost Per Test..... 13

 Tests Per FTE Per Day..... 14

 Cost Per FTE Per Day..... 15

 Laboratory Costs Per Procedure..... 16

LABORATORY SERVICES 16

LABORATORY SERVICES 17

HUMAN RESOURCES 17

III. KEY RECOMMENDATIONS..... 18

ORGANIZATIONAL STRUCTURE 18

SERVICE DELIVERY MODEL 18

Testing..... 19

 Test Menu Changes at SCG 20

Staffing 25

Equipment and Reagents..... 27

PHYSICIAN PLANNING 28

DEVELOPMENT OF LINKAGES AND AREAS OF REQUIRED SUPPORT 29

Transport (Hub and Spoke)..... 30

Management..... 30

Accreditation..... 31

BUDGET 31

Cost Reductions 31

New Costs..... 32

COMPARATIVE IMPACT 33



I. INTRODUCTION AND BACKGROUND

PROJECT PURPOSE AND OBJECTIVES

The Niagara Health System is undergoing ^{as} significant transformation as a result of the revised Health Services Restructuring Commission’s recommendations and the realignment of organization’s clinical care delivery model being structured around the programmatic approach. The Laboratory Medicine Program review project was designed to undertake an operations review to assess the current circumstances related to the delivery of laboratory services in the Region, and to position the NHS to make informed business and clinical decisions related to laboratory services within the context of the revised HSRC directions and programmatic approach.

- ❖ Documenting the strengths, issues and major risks associated with the current service delivery model, to serve as a basis for recommended service delivery enhancements.
- ❖ Developing a Laboratory Regional Service Delivery Plan that makes recommendations:
 - Test menu composition and referral patterns by site;
 - Management and organizational structures;
 - Human resources and staffing; and
 - Budget and financial components.

The project was divided into four phases:

- ❖ Phase 1 Initiate and gather data and information.
- ❖ Phase 2 Data analysis, data assessment and formulation.
- ❖ Phase 3 Identify strategic priorities, key results and strategies.
- ❖ Phase 4 Prepare draft report, and presentation to the NHS Laboratory Medicine Executive Committee and Senior Administration Team.

APPROACH AND METHODOLOGY

The project work included on-site visits to several hospitals (i.e., Welland Hospital Site (WHS), St. Catharines General Site (SCG), Greater Niagara General Site (GNG), Douglas Memorial Hospital Site (DMH), Port Colborne General Site (PCG), Shaver/Rehab Hospital (SRH), Niagara On The Lake Site (NTL) in the Region for information gathering purposes. The Hotel Dieu Hospital (HDH) had been visited in a previous engagement. Interviews with key regional laboratory staff at



- ❖ Site Supervisors and front line staff in hospitals including WHS, GNG, SCG and HDH.

Site Visits

The consultants visited major laboratory sites across the Region. These sites were selected as they operate as major centres in the Region and are able to provide insight on the issues and challenges faced from a service delivery perspective.

The site-specific information gathering process included the following:

- ❖ Hours of operation;
- ❖ Clinical services/programs supported;
- ❖ Laboratory services presently offered;
- ❖ Organizational structure;
- ❖ Work processes;
- ❖ Staffing;
- ❖ Site specific issues/problems; and
- ❖ Future considerations.

FINANCIAL AND VOLUME ANALYSIS

Financial and test volume data was collected and consolidated into a standardized regional framework using the MIS guidelines. The data was verified back to source documents including the financial data provided by the NHS financial system. The financial and test volume information presented in this report is as accurate as possible given the variety of sources. It should be noted that the test volume and financial data was revised on numerous occasions throughout the project and reviewed by the Laboratory Management Team.

The current budgets for all sites are as follows:



| Facility Name | 03/04 Actual | 04/05 Budget |
|--|---------------------|---------------------|
| St. Catharines General Lab Comb | \$4,147,214 | \$4,270,794 |
| St. Catharines General Pathology | \$961,073 | \$826,431 |
| CRP Lab Admin | \$5,055 | \$105,184 |
| St. Catharines General Pathology Reporting | \$47,639 | \$51,677 |
| St. Catharines Total | \$5,160,981 | \$5,254,086 |
| St. Catharines General Site | \$5,160,981 | \$5,254,086 |
| Hotel Dieu Hospital | \$2,703,853 | \$3,651,778 |
| Welland Hospital Site | \$2,769,292 | \$2,995,573 |
| Greater Niagara General Site | \$3,322,734 | \$3,485,127 |
| Douglas Memorial Hospital Site | \$864,815 | \$782,380 |
| Port Colborne General Site | \$994,135 | \$1,005,219 |
| Shaver/Rehab Hospital Site | \$200,612 | \$223,208 |
| Niagara on the Lake Site | \$145,106 | \$165,125 |
| NHS Regional TOTAL | \$16,161,528 | \$17,562,496 |

(The difference between the 03/04 actual and the budget for 04/05 is 8.7%.)

The following table indicates the number of on-site and referred tests completed in the Region, organized by facility:

| Summary of Test volumes in NHS | | | | |
|--------------------------------|------------------|---------------------|------------------|-----------------------------|
| Site | On-Site Volumes | Volume Referred Out | Total | On-Site as Percent of Total |
| Hotel Dieu Hospital | 417,370 | 17,361 | 434,731 | 96% |
| St. Catharines General | 589,894 | 63,632 | 652,526 | 90% |
| Greater Niagara General | 376,974 | 14,492 | 391,466 | 96% |
| Welland Hospital | 279,706 | 46,418 | 326,124 | 86% |
| Douglas Memorial Hospital | 69,689 | 5,014 | 74,703 | 93% |
| Port Colborne General | 89,687 | 12,561 | 102,248 | 88% |
| Niagara-On-The-Lake | | 57,200 | 57,200 | 0% |
| Shaver/Rehab Hospital | | 26,421 | 26,421 | 0% |
| Total | 1,823,320 | 243,099 | 2,065,419 | |

The breakdown of testing is as follows:

- ❖ The SCG site is the largest in both on-site testing and also in referred out testing. The HDH is the next largest with GNG and WHS following closely.
- ❖ When the HDH volumes are moved to SCG this will create a large testing site for the NHS.
- ❖ The current model is not well organized with very little transfer of testing between sites. The other hospitals not very strongly supported by SCG in testing patterns.
- ❖ The HDH has been outside of this model and worked independently.
- ❖ Neither NTL nor the SRH have onsite testing and all testing is send to MDS.
- ❖ All microbiology for the region is sent to MDS.
- ❖ Test referral and pattern changes within St. Catharines has decreased HDH test volumes and increased SCG volumes. *(Note: The HDH budget has not decreased over this same period, but has increased by \$947,925)*



II. KEY FINDINGS OF THE OPERATIONAL REVIEW OF LABORATORY SERVICES

NIAGARA HEALTH SYSTEM LABORATORY OVERVIEW

During the next year the provision of laboratory services in St. Catharines, will be centralized into the SCG location. The laboratory at the HDH will be closed and HDH will be responsible for the cost of the testing at the SRH (a rehabilitation hospital). This report will not discuss the current HDH situation but will deal with the transfer of testing to SCG. The funds for HDH to pay for these tests will be provided to them based upon the actual costs of the current volumes. The SCG will be the major testing site for the NHS within the Niagara Region.

Currently the PCG and the DMH sites provide services to very small communities with support offered from the WHS and the GNG site respectively.

NTL and the SRH do not provide any testing on site. All testing is transported to MDS and testing is provided by MDS.

A range of laboratory services are available throughout the Region based on population, referral patterns and clinical need. Services are provided in the following centres:

- ❖ St. Catharines – The SCG will be the major laboratory testing location for the Region; testing includes ; hematology, routine chemistry, immunology, coagulation, immunohematology, immunoassays, histology, cytology, morgue and autopsy services, and inpatient and outpatient phlebotomy
- ❖ St. Catharines – SRH -Inpatient phlebotomy is managed by MDS all testing goes to MDS;
- ❖ Niagara Falls – GNG testing includes; hematology, routine chemistry , immunology, coagulation, immunohematology, immunoassays and histology, inpatient phlebotomy;
- ❖ Welland – WHS testing includes; hematology, routine chemistry , immunology, coagulation, immunohematology, immunoassays and histology, inpatient and outpatient phlebotomy;
- ❖ Fort Erie – DMH testing includes hematology, routine chemistry , immunology, coagulation, immunohematology and immunoassays;
- ❖ Port Colborne – PCG testing includes includes hematology, routine chemistry , immunology, coagulation, immunohematology and immunoassays, inpatient and outpatient phlebotomy, EKG;
- ❖ Niagara-On-The-Lake – NTL provides inpatient phlebotomy and EKG, all testing goes to MDS.



A total of 1,823,320 tests were completed on-site in the NHS for 2004. Of this, approximately 1,007,264 (55%) were completed in St. Catharines. This is the combined SCG and HDH laboratories. And 656,680 (36%) were completed in the secondary hubs (i.e., WHS and GNG, with the later hospital completing 57% of the total) and 159,316 (8.7%) were completed in feeder hospitals (i.e. PCG and DMH).

Laboratory collection services are the only services available in the NTL and the SRH. Private laboratory collection services are also provided throughout the Region. The NHS provides consultative services, specifically pathology services on a regional basis with site Medicals Directors for all locations.

The NHS utilizes MDS, a private service provider for the following services:

- ❖ Management of the technical and business components of the NHS laboratory services
- ❖ Provision of a Regional Director of Operations and two (2) Laboratory Site Technical Managers
- ❖ Assistance with cytology technologist services
- ❖ Monthly operational reports
- ❖ Technical and quality support
- ❖ Transportation
- ❖ Responsibility for accreditation.




Quality Assurance

The NHS has created a new management position to support the Quality Assurance processes in the NHS. This position is working on the implementation of the QMP-LS accreditation guidelines. Quality Assurance is planned and implemented in a true regional model.

Transportation Networks

MDS provides transportation for the NHS. The current movement of specimens can be seen in the diagram below:



Laboratory Information System (LIS)

The NHS has a fully integrated LIS system. This has been excellently designed and implemented. The system in use for the NHS is Meditech. All testing results from MDS are available on this system.



COMPARISONS

Detailed comparative data for the NHS Laboratories is indicated below. (Note: This data is from the ORLSP process with the current NHS data and the percentage increase over the last 3 years indicated separately.)

The following table compares the NHS with multiple sites from within Ontario and outside Ontario. The yellow highlighted areas are where the indicator is the furthest from the group of values of the total hospitals and also from within the NHS/HDH. The purple highlighted area is where the indicators is the best from within the total hospital group and within the NHS/HDH.

| NHS 2001/02 Indicators | | | |
|---------------------------|---------------|------------------|-------------------|
| Location | Lab Cost/Test | Lab/Cost/FTE/Day | Lab Tests/FTE/Day |
| Hotel Dieu Hospital | \$ 7.81 | \$ 427.16 | 55 |
| St. Catharines General | \$ 7.62 | \$ 374.25 | 49 |
| Greater Niagara General | \$ 12.44 | \$ 374.50 | 30 |
| Welland Hospital | \$ 10.54 | \$ 422.79 | 40 |
| Douglas Memorial Hospital | \$ 12.01 | \$ 317.40 | 26 |
| Port Colborne Hospital | \$ 7.44 | \$ 418.67 | 56 |
| NHS/HDH Combined | \$ 9.04 | \$ 394.92 | 44 |
| Comparator A - 1 site | \$ 10.19 | \$ 428.50 | 42 |
| Comparator B - 2 sites | \$ 6.48 | \$ 420.12 | 65 |
| Comparator C - 2 sites | \$ 8.81 | \$ 356.73 | 41 |
| Comparator D - 5 sites | \$ 9.47 | \$ 395.67 | 42 |
| Comparator E - 1 site | \$ 7.75 | \$ 350.48 | 45 |
| Comparator F - 3 sites | \$ 5.98 | \$ 356.64 | 60 |
| Comparator G - 3 sites | \$ 5.79 | \$ 434.97 | 75 |
| Comparator H - 5 sites | \$ 8.21 | \$ 432.37 | 53 |

| NHS 2004/05 Indicators | | | |
|---------------------------|---------------|------------------|-------------------|
| Location | Lab Cost/Test | Lab/Cost/FTE/Day | Lab Tests/FTE/Day |
| Hotel Dieu Hospital | \$ 8.76 | \$ 536.08 | 61 |
| St. Catharines General | \$ 8.91 | \$ 519.49 | 58 |
| Greater Niagara General | \$ 9.25 | \$ 457.49 | 49 |
| Welland Hospital | \$ 10.71 | \$ 507.55 | 47 |
| Douglas Memorial Hospital | \$ 11.23 | \$ 470.18 | 42 |
| Port Colborne Hospital | \$ 11.21 | \$ 529.62 | 47 |
| NHS/HDH Combined | \$ 9.63 | \$ 512 | 53 |
| Hospital #1 | \$ 11.34 | \$ 580.52 | 51 |
| Hospital #2 | \$ 4.90 | \$ 419.28 | 86 |
| Hospital #3 | \$ 7.13 | \$ 279.30 | 39 |



Graphs

The data from the above tables have been arrayed in a series of graphs for greater clarity. Each of the three exhibits looks at a different set of data. This data provides information to the laboratories on their efficiency with respect to other peer hospitals.


- ❖ In each exhibit, the last bar is the NHS.
- ❖ Hospital #1 is a large Region in Alberta. This region consists of 20 hospitals, a single large geographic location and services provided by multiple private-sector providers.
- ❖ Hospital #2 is the [redacted] This is an academic health sciences centre that does referral work for [redacted] and beyond and supports two other sites that are not high volume. This hospital was used in the benchmarking as it has a high cost of transportation, services multiple sites but at the same time does high-cost esoteric testing.
- ❖ Hospital #3 is a small rural location in Ontario with multiple sites.
- ❖ Hospital #4 is a larger geographic centre in Ontario with dispersed population.

Benchmarking has inherent errors as each organization records and maintains different elements within the laboratory budgets. These hospitals were chosen as they represent the closest comparators to the NHS. It must be noted that the NHS is unique. This comparative information should therefore assist the NHS in the review of its laboratory services, but is not definitive of either efficiency or effectiveness. Again, benchmarking provides a basis for reviewing the operations of the laboratory and provides targets to move towards.



Cost Per Test


The cost per test graph indicates the total costs of operations against the total number of tests. A high cost per test will be seen in a site doing esoteric testing. In a laboratory providing high volume routine testing, this benchmark number should be low.



The NHS is at \$9.63 per test when not including the referred out testing volumes. The cost per test is slightly lower than that of Hospital #1 but above the other hospitals. Peer hospitals have considerably lower cost per test. Hospital #2 costs would be expected to be higher due to the esoteric nature of the testing. Both Hospital #1 and the NHS send testing to the private sector providers.




Tests Per FTE Per Day



The value for NHS is 53 tests per FTE per day. This number is slightly higher than Hospital #1 but lower than peer Hospital #4. Hospitals #1, 3 and 4 testing patterns would be very similar to NHS and the tests per FTE are also similar.



Cost Per FTE Per Day



Laboratory Costs Per Procedure

The table indicates the basis for estimating cost per procedure/test. The analysis provides the foundation for critically analyzing expenditures, especially as they relate to the relative value of having tests preformed at various sites.

| NHS 2003/04 Laboratory Cost Per Procedure | | | | | | |
|---|-----------------|----------------|----------------|----------------|----------------|----------------|
| Function | SCG | HDH | GNG | WHS | DMH | PCG |
| Staff - Medical | \$ 1.09 | \$ 1.32 | \$ 1.49 | \$ 1.67 | \$ 0.60 | \$ 0.54 |
| Staff - Technical/Clerical | \$ 3.45 | \$ 5.26 | \$ 3.79 | \$ 4.18 | \$ 5.15 | \$ 4.48 |
| Purchased and Contracted Services | \$ 8.14 | \$ 0.63 | \$ 0.51 | \$ 0.80 | \$ 1.64 | \$ 1.07 |
| Equipment and Supplies | \$ 1.23 | \$ 1.52 | \$ 0.95 | \$ 1.48 | \$ 1.77 | \$ 1.75 |
| Net Totals | \$ 13.91 | \$ 8.74 | \$ 6.76 | \$ 8.13 | \$ 9.17 | \$ 7.85 |



LABORATORY SERVICES

The HDH, SCG, GNG and the WHS are all operating 24 hours per day, 7 days per week. The DMH and the PCG are staffed two shifts per day with on call services in during the night. Testing is not provided at NTL or SRH.

Microbiology is referred out of the region to MDS.

Esoteric testing is also referred out to the PHL, Sick Kids, MDS or Hamilton Health Sciences Centre.

HUMAN RESOURCES


Technical staffing is comprised of Medical Laboratory Technicians and Medical Laboratory Assistants. Medical typists also provide clerical support to clinicians (i.e., transcribe anatomical pathologists reports, etc.) and administrative support where required. An appropriate complement of administrative staff is available to conduct duties such as reception, filing, typing, appointment scheduling and other related tasks.

The Laboratory Administrative Team consists of the Regional Medical Director, Site Medical Directors, Regional Director of Operations (MDS employee) and two site Managers (MDS employees). The team provides management, regional coordination and support specific to the delivery of laboratory services across the NHS.



III. KEY RECOMMENDATIONS

ORGANIZATIONAL STRUCTURE



SERVICE DELIVERY MODEL

The current service delivery model can be described as “distributed” with significant test menus at some of the smaller locations. The consultant proposes to introduce a full “hub and spoke” approach, decreasing the test type and volume at several of the smaller locations and enhancing the central “hub” laboratory at the SCG. Tests will also be relocated “upstream” from the DMH to the GNG and from the PCG to the WHS and redirected from NTL to SCG.



Testing

At the DMH, the consultant proposes to take advantage of its proximity to the GNG (approximately a 20 minute drive) to decant several tests now performed onsite to the GNG. Only phlebotomy and STAT testing will remain onsite.

The following tests will be transported to GNG:

| Code | Name | Volume |
|------|-----------------------|--------|
| L006 | Ethyl alcohol | 22 |
| L068 | Creatinine clearance | 1 |
| L073 | Drug Testing | 26 |
| L078 | Drugs of abuse screen | 105 |
| L378 | Bone Marrow | 1 |
| | | 155 |

To take further advantage of a full hub and spoke model, the following tests will be relocated from the GNG upstream to the SCG:

| Code | Name | Volume |
|------|--|--------|
| L001 | Acetone qualitative (should be quantitative) | 15 |
| L004 | Albumin qualitative | 49 |
| L040 | Carbamazepine | 162 |
| L055 | Cholesterol total | 850 |
| L068 | Creatinine clearance | 18 |
| L073 | Drug testing | 345 |
| L078 | Drugs of abuse screen | 539 |
| L085 | Electrophoresis | 173 |
| L117 | High-density Lipoprotein | 659 |
| L139 | Total Iron | 261 |
| L172 | Methemoglobin | 71 |
| L243 | Triglycerides | 829 |
| L304 | Aminoglycosides | 136 |
| L319 | Hepatitis | 474 |
| L321 | Theophylline | 29 |
| L324 | Dilantin | 284 |
| L329 | Ferritin | 636 |
| L339 | Free T4 | 223 |
| L341 | TSH | 1810 |
| L343 | Phenobarbitone | 34 |
| L377 | Bleeding time | 36 |
| L378 | Bone Marrow | 27 |
| L379 | Bone Marrow staining | 27 |
| L667 | Non-cultural direct bacterial antibody | 134 |
| L668 | Heterophile antibody screens | 93 |
| | | 7914 |



At the PCG, the consultant proposes to take advantage of its very close proximity to the WHS (approximately a ten minute drive) to decant several tests now performed onsite to the WHS. Only phlebotomy and STAT testing will remain onsite.

The following tests will be transported to WHS:

| Code | Name | Volume |
|------|-------------------------|------------|
| L078 | Drugs of abuse screen | 90 |
| L306 | Digoxin | 229 |
| L378 | Bone Marrow | 2 |
| L494 | Blood group per antigen | 245 |
| L661 | Cold agglutinins titre | 0 |
| | | 566 |

To take further advantage of a full hub and spoke model, the following tests will be relocated from the WHS upstream to the SCG:

| Code | Name | Volume |
|------|--------------------------|-------------|
| L040 | Carbamazepine | 190 |
| L055 | Cholesterol total | 185 |
| L068 | Creatinine clearance | 57 |
| L073 | Drug testing | 0 |
| L078 | Drugs of abuse screen | 779 |
| L190 | Phosphatase acid | 66 |
| L243 | Triglycerides | 159 |
| L304 | Aminoglycosides | 132 |
| L321 | Theophylline | 21 |
| L324 | Dilantin | 377 |
| L337 | Bleeding time | 12 |
| L348 | Phenobarbitone | 128 |
| L378 | Bone Marrow | 17 |
| L379 | Bone Marrow staining | 85 |
| L660 | Cold agglutinins screens | 10 |
| L661 | Cold agglutinins titre | 6 |
| | | 2219 |

Test Menu Changes at SCG

The changes indicated above will increase the volume of testing in the St. Catharines hub laboratory. In addition, a detailed analysis of the current referred-out test menu indicates that a substantial volume of tests are currently referred out to the private-sector provider that are more appropriately conducted onsite. These low-cost, high volume tests can be run on existing instrumentation using laboratory staff currently in the NHS system. The following table indicates tests and volumes currently undertaken by the private-sector provider to be performed by SCG:



| Code | Name | Volume |
|-------|--------------------------|--------|
| L005A | Albumin Quantitative | 756 |
| L018A | Amylase | 93 |
| L00A | Bilirubin, Total | 1214 |
| L031A | Bilirubin, conjugated | 11 |
| L040A | Carbamazepine Quant | 79 |
| L045A | Calcium | 511 |
| L046A | Calcium Ionized | 73 |
| L053A | Chloride | 6199 |
| L055A | Cholesterol Total | 3611 |
| L061A | CO2 Content | 4101 |
| L066A | Creatine Phosphokinase | 821 |
| L067A | Creatinine | 6793 |
| L068A | Creatinine Clearance | 64 |
| L107A | GGTP | 561 |
| L111A | Glucose Quantitative | 6347 |
| L117A | HDL Chol | 3055 |
| L139A | Iron TIBC | 484 |
| L146A | LDH | 582 |
| L157A | Lithium | 58 |
| L165A | Magnesium | 206 |
| L181A | Occult Blood | 727 |
| L191A | Phosphatase Alkaline | 1962 |
| L194A | Phosphorus | 329 |
| L204A | Potassium | 6256 |
| L208A | Protein Total | 448 |
| L222A | SGOT AST | 3316 |
| L223A | SGPT ALT | 1649 |
| L226A | Sodium | 6243 |
| L242A | Triglycerides | 3621 |
| L251A | Urea Nitrogen | 3007 |
| L252A | Uric Acid | 1107 |
| L253A | Urinalysis | 1480 |
| L254A | Urinalysis Micro | 1136 |
| L257A | Valproic Acid | 185 |
| L304A | Aminoglycosides | 72 |
| L306A | Digoxin | 164 |
| L309A | Folate, SR & RBC | 1563 |
| L419A | Hepatitis | 4502 |
| L324A | Dilantin | 167 |
| L329A | Ferritin | 1322 |
| L339A | Free T4 | 1182 |
| L341A | TSH | 4934 |
| L372A | Blood Film (WBC) | 126 |
| L375A | Blood Film Special Stain | 2 |
| L393A | CBC | 7764 |
| L398A | Reticulocyte Count | 77 |
| L402A | Fibrinogen, Quantitative | 11 |
| L406A | Fibrin | 14 |
| L432A | Malaria Smear | 2 |



| Code | Name | Volume |
|-------|------------------------|--------|
| L445A | Prothrombin time | 4815 |
| L451A | Sedimentation Rate | 802 |
| L452A | Sickle Cell Prep | 8 |
| L462A | Partial Thromboplastin | 213 |
| M10PA | PSA | 1857 |
| | | 96712 |

The closure of the laboratory at the HDH has by far the biggest impact on the hub laboratory at SCG. Presuming that the pattern of clinical practice remains the same at SCG as it was at HDH, the following HDH test volumes will move to SCG:

| Code | Name | Volume |
|------|------------------------------------|--------|
| L655 | Pregnancy | 939 |
| L668 | Heterophile antibodies -screen | 144 |
| L374 | Blood film buffy coat prep | 2 |
| L377 | Bleeding time | 84 |
| L378 | Bone Marrow | 802 |
| L379 | Bone marrow staining | 802 |
| L391 | CSF cell count | 34 |
| L393 | CBC | 38600 |
| L398 | Reticulocyte count | 670 |
| L406 | Fibrin split products latex screen | 720 |
| L424 | Hemosiderin | 1 |
| L432 | Malaria smear | 5 |
| L445 | Prothrombin time | 19512 |
| L451 | Sedimentation rate | 8756 |
| L462 | PTT | 7222 |
| L471 | Antibody Identification | 103 |
| L482 | Antibody screen | 2881 |
| L490 | Blood Group | 4163 |
| L492 | Crossmatch | 5626 |
| L493 | Blood Group - phenotype | 563 |
| L494 | Blood Group per antigen | 835 |
| L495 | Direct anti-human globulin | 120 |
| L001 | Acetone | 722 |
| L005 | Albumin quant | 5975 |
| L006 | Ethyl alcohol | 880 |
| L018 | Amylase | 1495 |
| L030 | Bilirubin total | 8105 |
| L031 | Bilirubin conjugated | 465 |
| L035 | pCO2, pOw and pH in comb. | 3800 |
| L045 | Calcium | 6195 |
| L053 | Chloride | 29567 |
| L055 | Cholesterol total | 178 |
| L059 | Acetaminophen | 588 |
| L061 | CO2 content | 27022 |
| L066 | Creatine Phosphokinase | 2507 |



| Code | Name | Volume |
|------|--------------------------------------|--------|
| L067 | Creatinine | 27171 |
| L068 | Creatinine clearance | 180 |
| L070 | Creatine Phosphokinase fractionation | 80 |
| L078 | Drugs of abuse screen | 284 |
| L107 | Gamma-glutamyl transpeptidase | 4919 |
| L111 | Glucose, quant | 18072 |
| L112 | Glucose, semi-quant | 21569 |
| L139 | Iron | 544 |
| L146 | LDH total | 5129 |
| L150 | Lipase | 1760 |
| L165 | Magnesium | 1180 |
| L181 | Occult Blood | 240 |
| L191 | Phosphatase, alkaline | 8666 |
| L194 | Phosphorus | 4951 |
| L197 | PBG screen | 0 |
| L204 | Potassium | 30056 |
| L208 | Protein | 3806 |
| L221 | Salicylate | 772 |
| L222 | SGOT | 9276 |
| L223 | SGPT | 5761 |
| L226 | Sodium | 29761 |
| L243 | Triglycerides | 172 |
| L251 | BUN | 29574 |
| L252 | Uric acid | 3665 |
| L253 | Urinalysis | 5917 |
| L254 | Urinalysis microscope | 2586 |
| L267 | Urobilin quant | 0 |
| U097 | PSA | 1506 |
| U116 | Troponin | 6237 |
| L304 | Aminoglycosides | 178 |
| L306 | Digoxin | 1115 |
| L319 | Hepatitis | 2423 |
| L321 | Aminophylline | 21 |
| L324 | Diphenhydantoin quant | 248 |
| L329 | Ferritin | 3432 |
| L341 | TSH | 1210 |
| L343 | Phenobarbitone | 64 |
| L345 | Vitamin B12 | 0 |
| L720 | Surgical pathology (Blocks) | 10700 |
| L721 | Consult (frozen section) | 54 |
| L731 | Immunoperoxidase | 439 |
| L705 | Aspiration biopsy | 160 |
| L706 | Bronchial washings | 29 |
| L708 | Gastric washings | 1 |
| L710 | Direct smears | 11 |
| L711 | Fluids | 2850 |
| L713 | Cervicovaginal specimen | 6 |



| Code | Name | Volume |
|------|-----------------------|--------|
| L715 | Smear for eosinophils | 0 |
| L716 | Sputum | 34 |
| | | 420781 |

The net effect of moving some tests upstream from the “spoke” hospital laboratories, others downstream from the current private sector provider and assuming all HDH tests move to SCG is to increase test volumes at the SCG hub laboratory by 528,347. This doubles the current size of the laboratory, and creates considerable opportunity for economy of scale.



Staffing

The following table indicates the proposed "before and after" staffing levels for each laboratory in the Niagara Health System:


| Site | Staffing | Before | After | Change |
|----------------------------------|------------------|--------|-------|--------|
| Niagara on the Lake | | | | |
| | Technologists | 0 | 0 | 0 |
| | Laboratory Aides | 1.1 | 1.1 | 0 |
| | Clerks | 0 | 0 | 0 |
| Port Colborne General | | | | |
| | Technologists | 5.1 | 3 | -2.1 |
| | Laboratory Aides | 2.2 | 2 | -0.2 |
| | Clerks | 0 | 0 | 0 |
| Douglas Memorial Hospital | | | | |
| | Technologists | 5.1 | 3 | -2.1 |
| | Laboratory Aides | 0.9 | 2 | 1.1 |
| | Clerks | 0.3 | 0 | -0.3 |
| Welland Hospital | | | | |
| | Technologists | 16.3 | 16.3 | 0 |
| | Laboratory Aides | 3.1 | 3.1 | 0 |
| | Clerks | 3.3 | 3.3 | 0 |
| Greater Niagara General | | | | |
| | Technologists | 18.5 | 18.5 | 0 |
| | Laboratory Aides | 6.6 | 6.6 | 0 |
| | Clerks | 4.2 | 4.2 | 0 |
| Hotel Dieu Hospital | | | | |
| | Technologists | 21.2 | 0 | -21.2 |
| | Laboratory Aides | 2.5 | 2.5 | 0 |
| | Clerks | 2.5 | 0 | -2.5 |
| St. Catharines General | | | | |
| | Technologists | 28.8 | 38 | 9.2 |
| | Laboratory Aides | 7 | 7 | 0 |
| | Clerks | 3.1 | 4.1 | 1 |

| SCG STAFFING MODEL | | |
|--------------------|-------------|-------------|
| | Current | Proposed |
| Core Lab | 17.7 | 25.7 |
| Histology | 5.6 | 6.6 |
| Cytology | 0.6 | 1.6 |
| Surgical Autopsy | 1.1 | 1.1 |
| Phlebotomy | 7 | 7 |
| Admin Clerical | 3.1 | 4 |
| Regional | 2.4 | 2.4 |
| Other | 0.7 | 0.7 |
| TOTAL | 38.2 | 49.1 |



The ratio of technologists to laboratory aides is approximately 3:1 throughout the system. In St. Catharines in the future it will be closer to 5.5:1. Some U.S. laboratory systems attempt to achieve a 1:1 ratio of technologists to laboratory aides. This would be a considerable risk for the NHS as the overall number of available technical staff is so low. There is, however, an opportunity in the future in the St. Catharine's core lab to address the projected imbalance through staff attrition and retirement.

The overall system staffing impact is indicated in the following graph:




The following table indicates the cost changes associated with this overall staffing impact:

| Overall System Impact | | | |
|-----------------------|--------------|----------|----------------------|
| | | Cost | Change |
| Technologists | -16.2 | \$65,000 | \$(1,053,000) |
| Laboratory Aides | 0.9 | \$35,000 | \$ 31,500 |
| Clerks | -1.8 | \$35,000 | \$ (63,000) |
| Total | -17.1 | | \$(1,084,500) |

The principal changes in the system are at the SCG hub laboratory. The consultant proposes the following changes to staffing levels at SCG:





Equipment and Reagents

A review of equipment occurred within the NHS. There has been a great deal of activity as the region is working on purchasing laboratory equipment under the DME funding. This will result in further equipment standardization. Other than replacing the aging chemistry equipment in the region, all other equipment is relatively new and standardized.

Costs for the introduction of a new blood bank gel system need to be added in PCG, GNG, WHS and SCG. HDH currently has a system that can be transferred and used elsewhere. The equipment costs for this procedure are minimal but the cost increase for the test is about \$2.00 per test. The test volume is about 15,000 ABO Rh tests per year. HDH does about 6,000 procedures and this can then be transferred to the SCG. This must be implemented to standardize within the region and insures that that NHS can meet the accreditation standards. (Equipment from HDH can be reused into the NHS.)

A review of the histopathology area at GNG determined that there is a very urgent need for an appropriate anatomical pathology grossing station with approved ventilation. Air monitoring was not performed but the fumes generated by this laboratory are very excessive and posses a health risk for the staff. A modern grossing station with good ventilation is recommended. Consider transferring grossing station from HDH (if it is transportable) to GNG when testing is moved to SCG. As well an automatic slide stainer is required for the SCG.



PHYSICIAN PLANNING

| | Surgical Volumes | Cytology Volumes | Total Volumes |
|-------------------------|---------------------|---------------------|------------------|
| Hotel Dieu Hospital | 11,192 | 3091 | 14,283 |
| St. Catharines General | 39,487 | 2170 | 41,657 |
| Greater Niagara General | 21,202 | 671 | 21,873 |
| Welland Hospital | 15,550 | 325 | 15,875 |
| Total | 87,431 | 6257 | 93,688 |

The above tables show the current status of the available physicians in the region and also the total funded positions that have either not been filled or are in the process of being recruited.

The transfer of these pathologists into the NHS will greatly reduce the considerable workload on the current physicians,

In the industry, there is a great deal of debate on what volume of work a pathologist should perform during the average workday. There are many factors that come into play. They include the complexity of the specimens, the body site from which the specimens were taken and if the laboratory supports a cancer program. Teaching and research activities also impact on the pathologist's productivity. The NHS does not undertake either teaching or research. This will lead to an increase in time available for service activities and therefore an increase in procedures/consultations per pathologist. Despite this, the current volume of activities undertaken by pathologists in the region is considerably higher than that undertaken in any comparable North American system.

This issue is being considered by the OMA and it is expected that performance targets will be agreed within a year. The workload at the NHS will likely far exceed the levels acceptable to the OMA. It is the consultant's recommendation that assistance be provided to the Medical Director to encourage the recruitment of pathologists to the NHS. It is also recommended that the NHS work with adjacent regions to review the probability of a physician collaborative that would offer support (financially and clinically) as needed to the pathologists within the NHS.



DEVELOPMENT OF LINKAGES AND AREAS OF REQUIRED SUPPORT

It is important the NHS maintain linkages to an Academic Health Science Centre. This offers a variety of supports that the NHS cannot obtain without this connection. They include:


- ❖ Access to new technologies and best practices
- ❖ Translation from Research to clinical relevance
- ❖ Support in problem solving of complex technical and medical problems
- ❖ Back up support for Medical and Technical crisis's.



Transport (Hub and Spoke)

The transportation flow will be streamlined to align with the new testing and site approach as follows:

Proposed Transportation



BUDGET

There are several contributors to the new budget:

Cost Reductions

- ❖ An overall reduction in the staffing costs of \$1,084,500
- ❖ An overall reduction in the costs of equipment and reagents of \$300,000
- ❖ Removal of the purchased service costs of \$200,000



- ❖ Cost reduction of moving costs to and restructuring referred out costs for a savings of \$132,008.
- ❖ Removal of the NTL referred out testing. This can be covered under the SCG testing costs. Savings of \$165,125.
- ❖ Decrease in reagent costs at PCG of \$200,000

New Costs

- ❖ One Laboratory Operations Director
- ❖ One Manager
- ❖ Operating costs associated with the system of \$45,000.

The Laboratory is a very capital and technologically intense area of healthcare. It is advisable to plan for continual updating and investment into new technologies and equipment.

The recommendations provide a background to development of an implementation plan. This plan will likely cover several years as the programs are moved within the NHS.



COMPARATIVE IMPACT

The following graphs illustrate the impact of these measures in comparative terms:

